8 Results

People

  1. Davey
    Davey
  2. Hancock
    Hancock
  3. Kumar
    Kumar
  4. Moskowitz
    Moskowitz
  5. Vardhana
    Vardhana
  6. Zelenetz
    Zelenetz
  7. Caron
    Caron
  8. Ganesan
    Ganesan
  9. Hamlin
    Hamlin
  10. Horwitz
    Horwitz

Groups

  1. Advanced Practice Providers (8)
  2. Center for Hematologic Malignancies (8)
  3. Department of Medicine (8)
  4. GSK Faculty (8)
  5. Hematologic Malignancies, Division of (8)
  6. Human Oncology and Pathogenesis Program (8)
  7. Lymphoma (8)
  8. Hematologic Malignancies Research (7)
  9. Molecular Imaging and Therapy Service (7)
  10. Population Sciences Research Program (7)
  1. "Center for Hematologic Malignancies"
  2. "Andrew Zelenetz"
  3. "GSK Faculty"
  4. "Helen Hancock"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (1)
Groups
  1. Advanced Practice Providers (8)
  2. Center for Hematologic Malignancies (8)
  3. Department of Medicine (8)
  4. GSK Faculty (8)
  5. Hematologic Malignancies, Division of (8)
  6. Human Oncology and Pathogenesis Program (8)

More Groups

People
  1. Alison Moskowitz (8)
  2. Andrew Zelenetz (8)
  3. Anita Kumar (8)
  4. Helen Hancock (8)
  5. Santosha Vardhana (8)
  6. Theresa Davey (8)

More People

Years
  1. 2023 (4)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (1)
Publications
  1. Blood (5)
  2. Hematological Oncology (2)
  3. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (5)
  2. Wiley Blackwell (2)
  3. American Society of Clinical Oncology (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save